ARCH Venture Partners LP (Southwest Headquarters)

6300 Bridgepoint Parkway Building One, Suite 500

Austin, TX 78730

512 795 5849

www.archventure.com

Abstract Description

Invests in the development of seed and early stage technology companies that have the potential to grow rapidly into successful businesses.

Management

Clinton W. Bybee Co-founder and Managing Director,Keith L. Crandell Co-founder and Managing Director, Kristina Burow Principal, Steven Lazarus Co-founder and Managing Director Emeritus, Robert T. Nelsen Co-founder and Managing Director, Steven Gillis Managing Director,Kristina Burow Partner, Paul Thurk Partner.

Keywords

information technology, physical sciences, life science, platform technologies, therapeutics, vaccines, diagnostics.

Comment | Printable Version | 1 of 1 | |

network/Financial and Investment/Venture Fund

Description

Invests in the development of seed and early stage technology companies that have the potential to grow rapidly into successful businesses. ARCH invests primarily in companies co-founded with leading scientists and entrepreneurs, concentrating on bringing to market innovations in life sciences, physical sciences, and information technology. We enjoy special recognition as a leader in the successful commercialization of technologies developed at academic research institutions and national laboratories

Program/Products/Services

ARCH Venture Partners is a premier provider of seed and early stage capital for technology firms, with a special competence in co-founding and building technology firms from startup.

Points of Differentiation

Many of ARCH's relationships with prestigious academic institutions, national research laboratories, leading financial organizations, and syndicate firms who participate in ARCH investments are long term. Some date back a decade or more.

Strategy/Focus

Their goal is to bring a concept or promising technology from its earliest stages to successful commercial applicationfrom concept to commerce.

Relevant Relationships

Vaccines (Aviron) Pain therapy (Adolor and NeurogesX) RNAi therapy (Alnylam Pharmaceuticals) Alternative antibodies (Trubion Pharmaceuticals) Anti-aging therapy (Elixir Pharmaceuticals) Genomics (deCode Genetics) Gene therapy (GenVec) Microfluidics (Caliper Life Sciences) Apoptosis (IDUN Pharmaceuticals) Nanotechnology (Nanosys) Addressable arrays (Illumina) Chemistry targeting (XenoPort) Chemistry outsourcing (Array BioPharma) Critical care therapy (Ikaria)

2012-02-04-864 SELECT * FROM `master` WHERE CompanyID='10506' AND `Profile_Type` LIKE 'resource' AND `Approved` LIKE 'YES' ORDER BY `Member_Priority` ASC LIMIT 0 , 30